Vanguard Global Advisers
IBO

Vanguard Global Advisers’s Impact BioMedical IBO Stock Holding History

Vanguard Global Advisers’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8K Hold
32,201
– – ﹤0.01% 3407
2026
Q1 		$19.3K Buy
+32,201
New +$16.1K ﹤0.01% 3320

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Vanguard Global Advisers's IBO Position: Q2 2026 in Review

Vanguard Global Advisers held its Impact BioMedical (IBO) position steady in Q2 2026 at 32,201 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3407.

Vanguard Global Advisers first reported a position in IBO in Q1 2026 and has held it in 2 quarters since. The position peaked at $19.3K in Q1 2026. 21 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • Vanguard Global Advisers held 32,201 shares of Impact BioMedical worth $14.8K as of Q2 2026.
  • Vanguard Global Advisers left its Impact BioMedical share count unchanged in Q2 2026.
  • Impact BioMedical made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3407 holding.
  • Vanguard Global Advisers first reported a position in Impact BioMedical in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Impact BioMedical position peaked at $19.3K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.